Inthera is a virtual company focusing on the disruption of protein-protein interactions (PPIs) using small molecule modulators. The oxopiperazine scaffold would potentially be a platform for the selective disruption of a multitude of helical protein-protein interactions.

Team Members
more about
Jasper Bos
more about
Cheryl Zimberlin
more about
Keno Gutierrez
Latest News Entry
M Ventures leads $11M round in solid tumor startup Inthera Bioscience

M Ventures has led a $10.8 million (€9.6 million) investment in Inthera Bioscience. The series A sets the Swiss biotech up to wrap up preclinical development of a lead candidate against cancers associated with human papillomavirus (HPV).

Inthera Bioscience raises EUR 3.4 million in seed financing round

Inthera Bioscience, a Swiss biopharmaceutical company focused on the development of first-in-class targeted small molecule therapies for solid tumors, today announced the closing

all portfolio news